These investigations aim to optimize the safety and effectiveness of chemoradiotherapy regimens while simultaneously reducing the associated side effects [522].Additionally, in silico and in vitro studies have provided evidence that EGCG targets NF-κB pathway, highlighting its potential as a therapeutic alternative for pancreatic cancer treatment by reducing cell growth, inducing apoptosis, and repressing NF-κB target genes [523]. The gene discussed is NFKB1; the disease is familial pancreatic carcinoma.